Cancer Institute– A national cancer institute
designated cancer center

Anthony Oro MD/PhD

Back to Profile

Publication Details

  • Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

    Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. N Engl J Med. 2012; 366 (23): 2171-9

    Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Although most basal-cell carcinomas are treated surgically, no effective therapy exists for locally advanced or metastatic basal-cell carcinoma. A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma.

    PubMedID: 22670903

Stanford Medicine Resources:

Footer Links: